Even voor mezelf om te bewaren:
Treatment
In the UK, both imidacloprid/ moxidectin and milbemycin are licensed to treat angiostrongylosis. Imidacloprid/moxidectin has been shown to be effective against both immature and mature Angiostrongylus stages, with an efficacy of 85 per cent in a blinded, randomised, controlled field study (Willesen et al, 2007; Schnyder et al, 2009a). Milbemycin has also been used successfully to treat field infections (Conboy 2004a). Although not licensed for treating A vasorum, fenbendazole has traditionally been used as the drug of choice, with doses of 25 mg/kg to 50 mg/kg sid suggested for three to 21 days, with similar efficacy to imidacloprid/moxidectin reported (Willesen et al, 2007).
Occasionally, patients will develop worsening respiratory signs after adulticides are administered, especially if worms are killed rapidly; these signs may need to be treated with steroids. Where bleeding is clinically significant, whole blood or fresh frozen plasma may be required. In dogs where disseminated intravascular coagulopathy (DIC) has been documented, transfusion products and heparin may also be considered. In cases with significant pulmonary hypertension, sildenafil is occasionally indicated; however, signs of pulmonary hypertension usually resolve quickly with treatment.
Studies have shown imidacloprid/moxidectin used in the prepatent period clears infection with L4 and immature adult worms, and this now carries a licence in the UK for prevention of angiostrongylosis (Schnyder et al, 2009b). Milbemycin can reduce parasite numbers if used in the prepatent period (Conboy et al, 2004b). Thus, in an endemic area, regular treatment with an effective drug is a sensible strategy to reduce the risks of developing disease.
Bron:
http://www.vettimes.co.uk/article/angio ... um-update/
A few dog wormers are approved in some countries for the control of Angiostrongylus vasorum (e.g. emodepside, fenbendazole, ivermectin, levamisole, milbemycin oxime, moxidectin). But they often require a special treatment regime to be determined by the veterinary doctor. It is not always clear at which extent they are effective against adult worms (i.e. for curing established infections) or against larvae (i.e. for preventing infections).
Bron:
http://parasitipedia.net/index.php?opti ... temid=2894
The use of various anthelmintics has been described
in the literature, among which fenbendazole, milbemycin
oxime and imidacloprid/moxidectin spot-on are
the most frequently used (Table 1). The treatment with
ivermectin and levamisole may have side effects. Anaphylactic
reactions due to the rapid killing of parasites
have been described after levamisole treatment (Bourque
et al., 2008). Fenbendazole, milbemycin oxime and
moxidectin/imidacloprid act more slowly, thereby reducing
the chance of adverse reactions. There is no difference
in efficacy between fenbendazole (25 mg/kg,
SID for 20 days) and imidacloprid 10%/moxidectin
2.5% (single topical dose of 0.1 ml/kg). However, fenbendazole
is not registered for this use in Europe
(Gould and McInnes, 1999; Conboy, 2004).
Bron:
http://vdt.ugent.be/sites/default/files/art80501.pdf
Treatment
Oxygen should be administered to animals with dyspnoea by nasal catheter, flow by or mask and low dose aspirin can be administered to animals considered to be at risk of developing pulmonary thromboembolism.
Infection with Angiostrongylus vasorum may be treated easily with suitable anthelmintics. Ideally, four 5 day courses of a benzimidazole should be administered at a high dose rate over 1-2 months. Fenbendazole is widely available in the UK in a granule form and this is used most frequently in the treatment of A. vasorum. If infection is suspected but larvae cannot be detected in faeces, it may still be worth treating the animal.
Alternatively, an imidacloprid/moxidectin spot-on can be used as a single application but this was found to have a lower efficacy than fenbendazole in the clearance of infection[10].
Bron:
https://en.wikivet.net/Angiostrongylosis
Ik weet niet, maar ik begrijp er eigenlijk geen reet van waarom Rolf Nijsse nu Advocate adviseerde ipv fenbendazole......